About
Developing the right medicines for the right time
What if we knew precisely how to treat or reverse early-stage disease, so it never progresses to later, more severe stages?
At Etiome, we know that many diseases begin to affect physiological processes well before symptoms emerge, and that these processes evolve as disease progresses. We have discovered that windows of the disease continuum are hidden within individual patient tissue, and that when uncovered and integrated across populations, these windows can reveal the full trajectory of disease, including its initial causes and downstream effects.
By applying single-cell omics and artificial intelligence, we uncover subtle, hidden patterns of progression to identify disease-modifying targets at critical inflection points for therapeutic intervention.
We believe that:
- Disease progression can be characterized by dynamic molecular and cellular representations with temporal resolution, enabling more precise target and biomarker discovery.
- Medicines designed for specific biological stages of disease, not just late-stage disease, will outperform one-size-fits-all approaches and unlock preemptive intervention.
- Biomarkers tied to underlying biology are dynamic across stages of disease and reveal responder populations for stage-specific therapeutics.
- Engaging individuals at the right biological moment, even during silent stages of disease, will enable earlier intervention, measurable impact, and better outcomes.
Origins
The name Etiome (EH-tee-ohm) emerged from the fusion of two powerful scientific concepts: etiology, or the cause of a disease, and omics, or the large-scale exploration of biological systems.
The combination reflects the company’s mission to develop the tools, insights, and medicines needed to create a true preemptive healthcare system that prioritizes long-term health and well-being. Originating from Flagship Pioneering’s Preemptive Health and Medicine initiative, an effort aimed at pioneering a new field to protect, maintain, or improve people's health before they get sick, Etiome was founded in 2021 with a vision of a healthier future.
Team
Leadership
Adrian Rawcliffe
Adrian “Ad” Rawcliffe joined Flagship Pioneering in 2026 as CEO-Partner and Chief Executive Officer of Etiome. Ad is a seasoned biotechnology leader with more than two decades of experience steering high-growth organizations through scientific, strategic, and financial inflection points.
Ad most recently served as CEO of Adaptimmune Therapeutics, where he led the registration of the first engineered TCR T-cell therapy for a solid tumor, orchestrated multiple strategic partnerships and M&A activities, and raised approximately $1.3B through a blend of capital markets and business development. Prior, as CFO, he guided Adaptimmune through its IPO and helped grow the company to more than 500 employees.
Before Adaptimmune, Ad spent more than 15 years at GSK in senior global roles, including SVP of Finance for North American Pharmaceuticals, SVP of Worldwide Business Development and R&D Finance, where he pioneered GSK’s first option-based R&D partnership model and led numerous external innovation and venture initiatives, and Managing Partner and President of SR One.
He currently serves as a non‑executive director of WAVE Life Sciences.
Ad began his career as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.
Scott Lipnick, Ph.D.
Scott Lipnick joined Flagship Pioneering in 2021. As an origination partner, he leads a team of entrepreneurs responsible for originating and growing Preemptive Health and Medicine. These companies focus on detecting and intervening against major diseases before traditional clinical diagnosis or significant changes in symptomology occur.
Prior to Flagship, Scott served as the vice president of life and data science at PatientsLikeMe – initially a subsidiary of UnitedHealth Group R&D and later Optum Ventures – where his team focused on generating and analyzing real-world and multi-omics data collected from individuals at key inflection points in disease onset and progression.
Before entering industry, Scott was a faculty member at the Harvard School of Medicine, Department of Biomedical Informatics and the Massachusetts General Hospital Center for Assessment Technology and Continuous Health. He also held affiliate positions at the Broad Institute, the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. His research aimed to extract value from data captured within insurance claims, electronic health records, and genomics using machine learning and artificial intelligence. Scott’s publications relate to advancing the understanding of disease onset and progression, identifying people at risk of disease before major clinical presentation, determining who will respond to a given intervention, and exploring druggable pathways that underlie specific forms of disease.
Scott received his B.S in Physics and Economics from Brandeis University and his Ph.D. in Biomedical Physics from the University of California, Los Angeles. Following his graduate studies, he was an AAAS Science and Technology Policy Fellow at the NIH Center for Regenerative Medicine.
Jean Lachowicz, Ph.D., MBA
Jean Lachowicz joined Etiome in 2025 as Chief Scientific Officer.
Jean brings nearly three decades of drug discovery and development experience to Etiome spanning multiple disease indications including neurology, oncology, immunology, rare disease, and cardiometabolic disease. She most recently served as SVP, Chief Development Scientist at Schrodinger, where she focused on asset strategy and portfolio optimization. Prior to Schrodinger, Lachowicz held additional leadership roles at companies including Celgene, Merck, and Schering Plough.
Jean has also served as an independent consultant for biotech companies and foundations, volunteered for Drew University’s RISE program, and contributed as a scientific reviewer on NIH study sections. Over her career, she has co-authored over 80 scientific articles, book chapters, and reviews.
Jean holds a Ph.D. in Pharmacology from Duke University and an MBA from Indiana University’s Kelley School of Business. She received her Sc.B. in Chemistry from Brown University.
Yann Echelard, Ph.D.
Yann Echelard is Chief Operating Officer at Etiome and Operating Partner at Flagship Pioneering. He joined Flagship Pioneering in 2018, focusing on internal biotechnology innovation and venture creation. Prior to Flagship, Yann was president and CEO at rEVO Biologics, which developed and commercialized therapeutics for thromboembolic disorders and critical care. At rEVO Biologics (and its predecessors Genzyme Transgenics and GTC Biotherapeutics) since 1994, Yann was initially involved with technology development leading to the commercial application of somatic cell nuclear transfer technology in large animals and to the regulatory approval of ATryn®, the first transgenically-derived therapeutic. Later, his involvement in business and corporate development culminated in the eventual acquisition of GTC by LFB SA, the French plasma fractionator. In addition to his role at rEVO and LFB, Yann was also engaged in spinning-out several companies out of the LFB group, such as Hema Biologics (focused on bleeding disorders), LFB-USA (transgenic platform), and TG Therapeutics.
Yann earned his Ph.D. from Université de Montréal in the laboratory of Dr. Alexandre Sasarman, working on the genetic characterization of heme biosyntesis pathway. After initial postdoctoral training in oncology at the Ludwig Institute Montreal branch (McGill University), he was a visiting scientist in the laboratory of Andy McMahon at the Roche Institute and at Harvard University where he worked on the regulation of Wnt-1 and on the isolation and functional characterization of the Hedgehog genes, the first identified vertebrate morphogens.
Yann is currently a director at TG Therapeutics (NASDAQ:TGTX), a New York City based biotechnology company focused the B-cell malignancies and auto-immune disorders.
Katharine von Herrmann, Ph.D.
Katharine is a co-founder of Etiome, and a principal at Flagship Pioneering where she works as part of a team of entrepreneurial scientists to explore new areas of biology and develop the science, intellectual property, and business strategy that form the foundation of Flagship’s life science ventures. Katharine is primarily focused on origination supporting Flagship’s Preemptive Health and Medicine initiative.
Before joining Flagship in 2020, Katharine earned her Ph.D. in Experimental and Molecular Medicine at Dartmouth. Her research focused on delineating the cellular and molecular mechanisms that underly the progression of Parkinson’s disease, and in doing so investigated the role of the NLRP3 inflammasome in neuroinflammation. Katharine was also a Healthcare Fellow for Borealis Ventures in Hanover, NH. Prior to her graduate studies, Katharine worked at the Spinal Muscular Atrophy Foundation, where she supported preclinical and clinical development of therapeutics for SMA.
Katharine holds a Ph.D. in Experimental and Molecular Medicine from the Guarini School of Graduate and Advanced Studies at Dartmouth. She received an M.S. in Biological Sciences and a B.A. in Biochemistry from Smith College.
Sandi Engle, PhD
Sandi Engle joined Etiome as Head of Biology in 2025. She has more than 20 years of broad experience leading groups focused on enabling drug discovery through the application of cutting-edge technologies including in vitro and in vivo models, stem cell biology, genomic editing, next generation sequencing, and computational biology.
Prior to joining Etiome, Sandi spent 8 years at Biogen leading various groups responsible for developing translational biology to support the drug discovery portfolio, eventually serving on the research leadership team. Additionally, she led partnered drug discovery programs involving a variety of modalities and worked closely with business development to evaluate novel technology opportunities.
At Vertex, Sandi served as the non-clinical liaison to regulatory affairs and assisted with the patient expansion of ivacaftor (Kalydeco) and the regulatory filings for ivacaftor-tezacaftor (Symdeko). At Pfizer and Aventis (now Sanofi), Sandi led a lab-based team developing in vivo and in vitro models.
Sandi has co-authored numerous scientific publications, chaired NIH grant review panels, and served on scientific advisory boards for scientific organizations and startups. Sandi received her BA from Ball State University and her PhD in Medical and Molecular Genetics from Indiana University School of Medicine.
Artem Sokolov, PhD
Artem joined Etiome as Head of Computational Biology in 2022. He has over 15 years of experience in machine learning and computational biology with extensive expertise in designing robust, interpretable methods that integrate naturally with biological domain knowledge.
Prior to joining Etiome, Artem was the head of Informatics & Modeling in the Laboratory of Systems Pharmacology at Harvard Medical School. In this role, he led a team of computational biologists, data scientists and software engineers who modeled preclinical and translational data across several disease areas, including cancer, Alzheimer’s Disease, and tuberculosis. Artem also played a key role in training and mentoring a diverse group of students and postdocs, and in managing the lab’s collaborations with academic and industrial groups in multiple large-scale consortia efforts.
Artem completed his PhD in computer science at Colorado State University under the supervision of Prof. Asa Ben-Hur and trained as a postdoctoral fellow with Prof. Josh Stuart at University of California, Santa Cruz. He has made key contributions to several national-level consortia, including The Cancer Genome Atlas, and co-authored over 50 publications throughout his career.
Founding Team
Noubar Afeyan, Ph.D.
Noubar Afeyan is founder and CEO of Flagship Pioneering. He is also co-founder and Board Chairman of Moderna.
Founded in 2000, Flagship is an enterprise where entrepreneurially-minded scientists invent seemingly unreasonable solutions to challenges facing human health and sustainability. They begin by asking “What if?” and iterate toward the unexpected answers resulting in the creation of first-in-category bioplatform companies with significant impact. Flagship has developed more than 100 scientific ventures resulting in over $100 billion in aggregate value, thousands of patents and patent applications, and more than 50 drugs in clinical development.
During his career as inventor, entrepreneur, and CEO, Noubar has cofounded and helped build over 100 life science and technology startups. Prior to founding Flagship Pioneering, Noubar was the founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he became senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics.
In addition to his role at Moderna (NASDAQ: MRNA), the pioneering messenger RNA medicines company, he is also co-founder and Board Chairman of Generate:Biomedicines. Previously, he was a member of the founding team, director, and investor in highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millenium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and Affinnova (acquired by AC Nielsen).
Noubar entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He has written numerous scientific publications and is the inventor of over 100 patents. He was a senior lecturer at MIT’s Sloan School of Management from 2000 to 2016, and a lecturer at Harvard Business School until 2020. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy.
Noubar’s commitment to improving the human condition through science and business goes hand in hand with social investments and a global humanitarian initiative. Together with his partners, he has launched philanthropic projects including the Aurora Humanitarian Initiative, FAST Foundation, and the UWC Dilijan School. Noubar is a member of the Corporation of MIT (the Institute’s governing body) and a member of the board of trustees for the Boston Symphony Orchestra.
Noubar was born in Beirut to Armenian parents in 1962, did his undergraduate work at McGill University in Montreal, and completed his Ph.D. in biochemical engineering at MIT in 1987. A passionate advocate of the contributions of immigrants to economic and scientific progress, Noubar received the Golden Door Award in 2017 from the International Institute of New England, in honor of his outstanding contributions to American society as a U.S citizen of foreign birth. He was also awarded a Great Immigrant honor from the Carnegie Corporation in 2016, received a Technology Pioneer award from the World Economic Forum in 2012, and was presented with the Ellis Island Medal of Honor in 2008. In 2022, Noubar was elected to the National Academy of Engineering.
Avak Kahvejian, Ph.D.
Avak Kahvejian, Ph.D. is a life sciences inventor and entrepreneur. As President of Flagship Labs, Flagship Pioneering’s innovation engine, Avak leads multidisciplinary teams that originate, test, and scale breakthrough scientific ideas with the potential to transform human health and sustainability, spanning AI-based biology platforms, generative AI platforms for multiple therapeutic modalities, first-in-kind gene and cell therapies, and high-throughput enabling technologies.
Since joining Flagship in 2011, he has co-founded more than ten high-value public and private companies, including Seres Therapeutics (NASDAQ: MCRB), Ring Therapeutics, Cellarity, Sail Biomedicines, Generate:Biomedicines (NASDAQ: GENB), ProFound Therapeutics, Ampersand Biomedicines, Abiologics, Etiome, Rubius Therapeutics, and Codiak BioSciences. Avak has served as founding President and CEO of Rubius Therapeutics, co-CEO of Generate Biomedicines, and founding CEO of several Flagship-founded companies, including Cellarity, Laronde, Ring, ProFound, Ampersand, Abiologics, and Etiome. He currently serves on the boards of Cellarity, Sail, Ring, and Etiome, and is Chairman of Ampersand, ProFound, and Abiologics.
Prior to joining Flagship, Avak was Vice President of Business Development at Helicos BioSciences, where he helped develop and commercialize the world’s first single-molecule DNA sequencing technology.
Avak currently serves as Chairman of the Board of the International Institute of New England, an institution which creates opportunities for refugees and immigrants to succeed through resettlement, education, career advancement and pathways to citizenship. He is also on the Board of Genome Canada, the Advisory Board of the Foundation for Armenian Science and Technology (FAST), and the McGill University Regional Advisory Board US.
He earned his Ph.D. and B.Sc. in Biochemistry from McGill University in Montreal, Canada.
Scott Lipnick, Ph.D.
Scott Lipnick joined Flagship Pioneering in 2021. As an origination partner, he leads a team of entrepreneurs responsible for originating and growing Preemptive Health and Medicine. These companies focus on detecting and intervening against major diseases before traditional clinical diagnosis or significant changes in symptomology occur.
Prior to Flagship, Scott served as the vice president of life and data science at PatientsLikeMe – initially a subsidiary of UnitedHealth Group R&D and later Optum Ventures – where his team focused on generating and analyzing real-world and multi-omics data collected from individuals at key inflection points in disease onset and progression.
Before entering industry, Scott was a faculty member at the Harvard School of Medicine, Department of Biomedical Informatics and the Massachusetts General Hospital Center for Assessment Technology and Continuous Health. He also held affiliate positions at the Broad Institute, the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. His research aimed to extract value from data captured within insurance claims, electronic health records, and genomics using machine learning and artificial intelligence. Scott’s publications relate to advancing the understanding of disease onset and progression, identifying people at risk of disease before major clinical presentation, determining who will respond to a given intervention, and exploring druggable pathways that underlie specific forms of disease.
Scott received his B.S in Physics and Economics from Brandeis University and his Ph.D. in Biomedical Physics from the University of California, Los Angeles. Following his graduate studies, he was an AAAS Science and Technology Policy Fellow at the NIH Center for Regenerative Medicine.
Torben Straight Nissen, Ph.D.
Torben Straight Nissen is an Executive Partner at Flagship Pioneering and the CEO of Repertoire Immune Medicines. In his role at Flagship, he contributes to the company’s strategic and operational objectives, including establishing its Preemptive Health and Medicine initiative and providing executive leadership to portfolio companies such as Rubius Therapeutics and Generate:Biomedicines. He currently serves on the board of Repertoire Immune Medicines and Etiome.
Torben has provided executive and R&D leadership to biotech and pharmaceutical companies for more than 20 years. Prior to joining Flagship, Torben was at Pfizer where he headed up Strategic Portfolio Management for the company’s worldwide R&D organization. In this role, he oversaw Pfizer’s portfolio, spanning from discovery to Phase 2b across Pfizer’s 300+ programs in all major therapeutic areas. Earlier in his career, Torben served as Chief Operating officer for Ascendis Pharma (Nasdaq: ASND) and Managing Director for Maxygen Inc.
Torben is a co-author or co-inventor of more than 100 publications and published patents. He holds a Ph.D. in molecular biology and biochemical engineering from the Technical University of Denmark and Carlsberg Laboratories and a Master of Science degree in chemical engineering from the Technical University of Denmark.
Yann Echelard, Ph.D.
Yann Echelard is Chief Operating Officer at Etiome and Operating Partner at Flagship Pioneering. He joined Flagship Pioneering in 2018, focusing on internal biotechnology innovation and venture creation. Prior to Flagship, Yann was president and CEO at rEVO Biologics, which developed and commercialized therapeutics for thromboembolic disorders and critical care. At rEVO Biologics (and its predecessors Genzyme Transgenics and GTC Biotherapeutics) since 1994, Yann was initially involved with technology development leading to the commercial application of somatic cell nuclear transfer technology in large animals and to the regulatory approval of ATryn®, the first transgenically-derived therapeutic. Later, his involvement in business and corporate development culminated in the eventual acquisition of GTC by LFB SA, the French plasma fractionator. In addition to his role at rEVO and LFB, Yann was also engaged in spinning-out several companies out of the LFB group, such as Hema Biologics (focused on bleeding disorders), LFB-USA (transgenic platform), and TG Therapeutics.
Yann earned his Ph.D. from Université de Montréal in the laboratory of Dr. Alexandre Sasarman, working on the genetic characterization of heme biosyntesis pathway. After initial postdoctoral training in oncology at the Ludwig Institute Montreal branch (McGill University), he was a visiting scientist in the laboratory of Andy McMahon at the Roche Institute and at Harvard University where he worked on the regulation of Wnt-1 and on the isolation and functional characterization of the Hedgehog genes, the first identified vertebrate morphogens.
Yann is currently a director at TG Therapeutics (NASDAQ:TGTX), a New York City based biotechnology company focused the B-cell malignancies and auto-immune disorders.
Katharine von Herrmann, Ph.D.
Katharine is a co-founder of Etiome, and a principal at Flagship Pioneering where she works as part of a team of entrepreneurial scientists to explore new areas of biology and develop the science, intellectual property, and business strategy that form the foundation of Flagship’s life science ventures. Katharine is primarily focused on origination supporting Flagship’s Preemptive Health and Medicine initiative.
Before joining Flagship in 2020, Katharine earned her Ph.D. in Experimental and Molecular Medicine at Dartmouth. Her research focused on delineating the cellular and molecular mechanisms that underly the progression of Parkinson’s disease, and in doing so investigated the role of the NLRP3 inflammasome in neuroinflammation. Katharine was also a Healthcare Fellow for Borealis Ventures in Hanover, NH. Prior to her graduate studies, Katharine worked at the Spinal Muscular Atrophy Foundation, where she supported preclinical and clinical development of therapeutics for SMA.
Katharine holds a Ph.D. in Experimental and Molecular Medicine from the Guarini School of Graduate and Advanced Studies at Dartmouth. She received an M.S. in Biological Sciences and a B.A. in Biochemistry from Smith College.
Board of Directors
Torben Straight Nissen, Ph.D.
Torben Straight Nissen is an Executive Partner at Flagship Pioneering and the CEO of Repertoire Immune Medicines. In his role at Flagship, he contributes to the company’s strategic and operational objectives, including establishing its Preemptive Health and Medicine initiative and providing executive leadership to portfolio companies such as Rubius Therapeutics and Generate:Biomedicines. He currently serves on the board of Repertoire Immune Medicines and Etiome.
Torben has provided executive and R&D leadership to biotech and pharmaceutical companies for more than 20 years. Prior to joining Flagship, Torben was at Pfizer where he headed up Strategic Portfolio Management for the company’s worldwide R&D organization. In this role, he oversaw Pfizer’s portfolio, spanning from discovery to Phase 2b across Pfizer’s 300+ programs in all major therapeutic areas. Earlier in his career, Torben served as Chief Operating officer for Ascendis Pharma (Nasdaq: ASND) and Managing Director for Maxygen Inc.
Torben is a co-author or co-inventor of more than 100 publications and published patents. He holds a Ph.D. in molecular biology and biochemical engineering from the Technical University of Denmark and Carlsberg Laboratories and a Master of Science degree in chemical engineering from the Technical University of Denmark.
Avak Kahvejian, Ph.D.
Avak Kahvejian, Ph.D. is a life sciences inventor and entrepreneur. As President of Flagship Labs, Flagship Pioneering’s innovation engine, Avak leads multidisciplinary teams that originate, test, and scale breakthrough scientific ideas with the potential to transform human health and sustainability, spanning AI-based biology platforms, generative AI platforms for multiple therapeutic modalities, first-in-kind gene and cell therapies, and high-throughput enabling technologies.
Since joining Flagship in 2011, he has co-founded more than ten high-value public and private companies, including Seres Therapeutics (NASDAQ: MCRB), Ring Therapeutics, Cellarity, Sail Biomedicines, Generate:Biomedicines (NASDAQ: GENB), ProFound Therapeutics, Ampersand Biomedicines, Abiologics, Etiome, Rubius Therapeutics, and Codiak BioSciences. Avak has served as founding President and CEO of Rubius Therapeutics, co-CEO of Generate Biomedicines, and founding CEO of several Flagship-founded companies, including Cellarity, Laronde, Ring, ProFound, Ampersand, Abiologics, and Etiome. He currently serves on the boards of Cellarity, Sail, Ring, and Etiome, and is Chairman of Ampersand, ProFound, and Abiologics.
Prior to joining Flagship, Avak was Vice President of Business Development at Helicos BioSciences, where he helped develop and commercialize the world’s first single-molecule DNA sequencing technology.
Avak currently serves as Chairman of the Board of the International Institute of New England, an institution which creates opportunities for refugees and immigrants to succeed through resettlement, education, career advancement and pathways to citizenship. He is also on the Board of Genome Canada, the Advisory Board of the Foundation for Armenian Science and Technology (FAST), and the McGill University Regional Advisory Board US.
He earned his Ph.D. and B.Sc. in Biochemistry from McGill University in Montreal, Canada.
Raj Panjabi, M.D.
Raj Panjabi, M.D. is responsible for leading Flagship’s Preemptive Health and Medicine Initiative, which is pioneering a new field to protect, maintain, or improve people’s health before they get sick.
Raj is former White House Senior Director and globally recognized as a distinguished authority in healthcare, public policy, entrepreneurship, and technology.
As White House Senior Director, Raj served as President Biden’s top pandemic and health official at the National Security Council, where he played a pivotal role in the largest vaccination campaign in history against COVID-19 and responses to public health crises, including mpox, influenza and Ebola. He played a lead role executing the 2022 National Biodefense Strategy and American Pandemic Preparedness Plan, coordinating over $12 billion in annual investment across 16 federal agencies in biodefense, including in diagnostics, therapeutics, and vaccines. Raj also helped oversee implementation of the President’s 2022 Executive Order to Advance Biotechnology and Biomanufacturing Innovation and the 2022 U.S. Global Health Security Act, authorizing $5 billion and expanding health investments across 50 countries. He co-developed President Biden’s COVID-19 and health security initiatives with the G7, G20, and regional bodies, and efforts to organize Presidential Summits, launch the Pandemic Fund at the World Bank, negotiate the WHO International Health Regulations and Pandemic Accord, and uphold the UN Biological Weapons Convention.
Previously, Raj led the President’s Malaria Initiative, helping launch the world’s first malaria vaccine, create a strategy to prevent 1 billion cases, and manage a $800 million enterprise protecting 700 million people across 30 countries. Raj is co-founder and former CEO of Last Mile Health, a global organization transforming community health systems.
Raj has been a senior advisor to several biotech companies and has served on the boards of private sector companies, non-profits, and other initiatives. He currently serves on the boards of WHO Foundation, Skoll Foundation, Last Mile Health, among others, and on the Bipartisan Commission on Biodefense. He serves on the faculty at Harvard Medical School and Brigham and Women’s Hospital.
One of TIME’s 100 Most Influential People in the World and TIME’s 50 Most Influential People in Healthcare, and twice named to the FORTUNE World’s 50 Greatest Leaders list, Raj has received the TED Prize, Clinton Global Citizen Award, and World Economic Forum’s Social Entrepreneur of the Year award. He was knighted by President Ellen Johnson Sirleaf and the Government of Liberia. He trained in biochemistry, epidemiology and biostatistics, and medicine at the University of North Carolina at Chapel Hill, Johns Hopkins University, Harvard Medical School, and Massachusetts General Hospital.
Gregory J. Moore, M.D., Ph.D.
Gregory J. Moore, M.D., Ph.D. is an engineer and physician, board certified in Diagnostic Radiology, Neuroradiology and Clinical informatics. Dr. Moore previously served as the Corporate Vice President at Microsoft where he led Microsoft’s Health & Life Sciences research, cloud and AI product business. Prior to joining Microsoft, Dr. Moore served as the Vice President and Founder of Google Cloud Healthcare & Life Sciences. Dr. Moore’s prior academic and clinical appointments include Stanford, Geisinger Health System, Penn State, and Wayne State. Dr. Moore currently serves as a Senior Advisor to Gates Ventures and also serves as an independent director of several public and private company boards. Dr. Moore holds a Ph.D. in Radiological Sciences from Massachusetts Institute of Technology, and M.D. from Wayne State University School of Medicine.
